Carbohydrate-associated Immunodominant Epitope(s) of CA215

Abstract

RP215 monoclonal antibody (Mab) was initially generated against OC-3-VGH ovarian cancer cells and was shown to react with a cancer-associated carbohydrate epitope in glycoproteins designated as CA215. Additional five high affinity Mabs, designated as RCA-10, -100, -104, -110 and -111, respectively, were generated by using affinity-purified CA215 as the immunogen in this study. All RCA Mabs were found to recognize periodate-sensitive carbohydrate-associated epitope(s) and to pair with RP215 in typical sandwich enzyme immunoassays for the quantification of CA215. When compared with those of RP215, the amino acid sequence homology of the Fab regions ranged from 100% for RCA-100 to 65% for RCA-110, based on which 3 distinct Mab groups were categorized. In vitro TUNEL apoptosis and complement-dependent cytotoxicity assays were performed with these Mabs and found to have comparable inhibitory efficacy to cancer cells. Results of biochemical and immunological assays revealed that RP215, RCA-100 and RCA-10 react with the linear carbohydrate-associated epitope, whereas the others recognize the conformational form of the epitope in CA215. This study has suggested that the unique carbohydrate-associated epitope(s) is immunodominant in mice when immunized with CA215. It remains to be demonstrated if the differential anti-cancer efficacy exists among the distinct groups of these anti-CA215 Mabs.

• Carbohydrate-associated epitopes
• Immunoglobulin superfamily proteins
• Monoclonal antibody
• RCA
• RP215

ACKNOWLEDGEMENTS

This project was supported in parts by Vancouver Biotech Ltd (#090401). The NSERC and IRAP support (#743918) of the following co-op students/research assistants are also acknowledged: Brett Giolma, Jie Pan, Fong Shan Hsu, Ming Shen Liu, Suzanne Potzold, Eric Wong.

Declaration of interest: GL is co-founder of Vancouver Biotech Ltd. The authors alone are responsible for the content and writing of the paper.